Is The Santa Claus Rally The Gift That Keeps Giving?
Remember the horror of 2008 when the Great Recession hit…
Buy
62
EHC Quote, Financials, Valuation and Earnings
Last price:
$94.18
Seasonality move
:
2.92%
Day range:
$93.31 - $94.38
52-week range:
$65.99 - $104.55
Dividend yield:
0.66%
P/E ratio:
22.75x
P/S ratio:
1.84x
P/B ratio:
4.84x
Volume:
135.4K
Avg. volume:
640.3K
1-year change:
40.18%
Market cap:
$9.5B
Revenue:
$4.8B
EPS (TTM):
$4.14
Analysts' Opinion
-
Consensus RatingEncompass Health has received a consensus rating of --. The company's average rating is a -- based on 0 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of --, Encompass Health has an estimated upside of 23.71% from its current price of $94.17.
-
Price Target DownsideAccording to analysts, the lowest downside price target is -- representing 100% downside risk from its current price of $94.17.
Fair Value
-
According to the consensus of 0 analysts, Encompass Health has 23.71% upside to fair value with a price target of -- per share.
EHC vs. S&P 500
-
Over the past 5 trading days, Encompass Health has underperformed the S&P 500 by -5.64% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Encompass Health does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Encompass Health has grown year-over-year revenues for 9 quarters straight. In the most recent quarter Encompass Health reported revenues of $1.4B.
Earnings Growth
-
Encompass Health has grown year-over-year earnings for 3 quarters straight. In the most recent quarter Encompass Health reported earnings per share of $1.06.
Enterprise value:
12.7B
EV / Invested capital:
2.39x
Price / LTM sales:
1.84x
EV / EBIT:
14.88x
EV / Revenue:
2.43x
PEG ratio (5yr expected):
1.24x
EV / Free cash flow:
47.06x
Price / Operating cash flow:
35.66x
Enterprise value / EBITDA:
11.09x
Gross Profit (TTM):
$5B
Return On Assets:
6.78%
Net Income Margin (TTM):
8.1%
Return On Equity:
17.39%
Return On Invested Capital:
8.26%
Operating Margin:
15.48%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $4.3B | $4.7B | $5.2B | $1.2B | $1.4B | |
| Gross Profit | $4.1B | $4.5B | $5B | $1.2B | $1.3B | |
| Operating Income | $601.6M | $721.6M | $822.1M | $179.4M | $209.1M | |
| EBITDA | $829.8M | $1B | $1.1B | $248.2M | $297.1M | |
| Diluted EPS | $2.72 | $3.50 | $4.14 | $0.84 | $1.06 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $1.2B | $909.8M | $733.8M | $813.7M | $933.9M | |
| Total Assets | $6.6B | $6.7B | $5.5B | $6B | $6.5B | |
| Current Liabilities | $682.5M | $793.9M | $604.7M | $639.2M | $897.4M | |
| Total Liabilities | $4.7B | $4.4B | $3.7B | $3.8B | $3.7B | |
| Total Equity | $1.9B | $2.3B | $1.7B | $2.2B | $2.7B | |
| Total Debt | $3.6B | $3.2B | $2.7B | $2.7B | $2.6B | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $657.4M | $822M | $925M | $215.2M | $267.8M | |
| Cash From Investing | -$641.3M | -$601.1M | -$657.7M | -$162.2M | -$161.5M | |
| Cash From Financing | -$86.9M | -$183.8M | -$209.6M | -$65.8M | -$89.5M | |
| Free Cash Flow | $81M | $241.4M | $269.5M | $65.5M | $120.3M | |
EHC
Sector
Market Cap
$9.5B
$46.1M
Price % of 52-Week High
90.07%
46.02%
Dividend Yield
0.66%
0%
Shareholder Yield
--
-0.6%
1-Year Price Total Return
40.18%
-30.52%
Beta (5-Year)
0.876
0.772
Dividend yield:
0.66%
Annualized payout:
$0.60
Payout ratio:
14.37%
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$95.48
200-day SMA
Buy
Level
$89.64
Bollinger Bands (100)
Sell
Level
90.66 - 100.42
Chaikin Money Flow
Buy
Level
247.3M
20-day SMA
Sell
Level
$99.46
Relative Strength Index (RSI14)
Sell
Level
29.19
ADX Line
Sell
Level
25.09
Williams %R
Buy
Level
-88.6584
50-day SMA
Sell
Level
$99.26
MACD (12, 26)
Sell
Level
-1.64
25-day Aroon Oscillator
Sell
Level
-68
On Balance Volume
Neutral
Level
39.2M
Financial Scores
Hold
Altman Z-Score
(Annual)
Level (2.3771)
Sell
CA Score
(Annual)
Level (-0.7062)
Buy
Beneish M-Score
(Annual)
Level (-2.6584)
Buy
Momentum Score
Level (9)
Buy
Ohlson Score
Level (0.0118)
Buy
Piotroski F Score
(Annual)
Level (9)
Buy
Quality Ratio Score
Level (7)
Buy
Fundamental Score
Level (9)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Encompass Health Corp provides post-acute healthcare services in the United States through a network of inpatient rehabilitation hospitals. Inpatient rehabilitation contributes the majority of the firm's revenue and provides specialized rehabilitative treatment through a network of inpatient hospitals. These hospitals are concentrated in the eastern half of the United States and Texas.
Stock Forecast FAQ
In the current month, EHC has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The EHC average analyst price target in the past 3 months is --.
-
Where Will Encompass Health Stock Be In 1 Year?
According to analysts, the consensus estimate is that Encompass Health share price will rise to -- per share over the next 12 months.
-
What Do Analysts Say About Encompass Health?
Analysts are divided on their view about Encompass Health share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Encompass Health is a Sell and believe this share price will drop from its current level to --.
-
What Is Encompass Health's Price Target?
The price target for Encompass Health over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is EHC A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Encompass Health is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of EHC?
You can purchase shares of Encompass Health via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Encompass Health shares.
-
What Is The Encompass Health Share Price Today?
Encompass Health was last trading at $94.18 per share. This represents the most recent stock quote for Encompass Health. Yesterday, Encompass Health closed at $94.17 per share.
-
How To Buy Encompass Health Stock Online?
In order to purchase Encompass Health stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Alphabet an Undervalued Growth Stock to Buy?
Alphabet (NASDAQ:GOOGL) is easily one of the most successful companies…
Is Tesla Going to Buy Uber?
Tesla has always been in the habit of making large,…
Stock Ideas
Buy
65
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 42x
Buy
57
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 118x
Buy
58
Is MSFT Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 37x
Alerts
Buy
87
PSIX alert for Dec 25
Power Solutions International [PSIX] is up 27.42% over the past day.
Buy
65
TSLL alert for Dec 25
Direxion Daily TSLA Bull 2X Shares [TSLL] is up 19.46% over the past day.
Buy
75
SMLR alert for Dec 25
Semler Scientific [SMLR] is up 15.37% over the past day.
